PubMed Health⌕ Search

PubMed · 14560686

[Inhalation corticosteroids for COPD: possible less mortality].

Abstract

General practitioners find it difficult to accurately distinguish asthma from COPD. However, this differential diagnosis is important, as the treatment of the two entities is different. Asthma is by definition steroid responsive, whereas several long-term trials have demonstrated that in COPD, the lung function is not affected by steroid treatment. Yet it is questionable whether lung function is a good parameter for evaluating treatment effects, as there are indications that steroids affect the quality of life and the number of exacerbations. Moreover, an observational study has shown that inhaled steroids might affect mortality. Observational studies do not normally provide conclusive evidence, due to the possible inclusion of many confounding factors (such as confounding by indication). Nevertheless, this observational study indicates that it might be possible to treat COPD with steroids. A large prospective randomised trial that is currently in progress will need to confirm whether or not this is the case.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C P van Schayck, P N Dekhuijzen. 2003-09-27. [Inhalation corticosteroids for COPD: possible less mortality].. https://pubmed.ncbi.nlm.nih.gov/14560686/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗